Pfizer secures expanded pediatric indication for Prevenar 13 in Europe
This article was originally published in Scrip
Executive Summary
The European Commission has approved an expanded indication for Pfizer's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), extending its use to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae.